BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15121032)

  • 1. HDL: a recipe for longevity.
    Barter P
    Atheroscler Suppl; 2004 May; 5(2):25-31. PubMed ID: 15121032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions.
    Barter P; Kastelein J; Nunn A; Hobbs R;
    Atherosclerosis; 2003 Jun; 168(2):195-211. PubMed ID: 12801602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High density lipoprotein: guardian of the vascular system?
    Packard C; Nunn A; Hobbs R;
    Int J Clin Pract; 2002 Dec; 56(10):761-71. PubMed ID: 12510950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
    Chapman MJ
    Pharmacol Ther; 2006 Sep; 111(3):893-908. PubMed ID: 16574234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of HDL in those with diabetes.
    Santos-Gallego CG; Rosenson RS
    Curr Cardiol Rep; 2014 Aug; 16(8):512. PubMed ID: 24950673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDL-c is a powerful lipid predictor of cardiovascular diseases.
    Bruckert E; Hansel B
    Int J Clin Pract; 2007 Nov; 61(11):1905-13. PubMed ID: 17655681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-density lipoprotein cholesterol in the cardiovascular equation: does the "good" still count?
    Alsheikh-Ali AA; Kuvin JT; Karas RH
    Atherosclerosis; 2005 Jun; 180(2):217-23. PubMed ID: 15910846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should low high-density lipoprotein cholesterol (HDL-C) be treated?
    Toth PP; Barylski M; Nikolic D; Rizzo M; Montalto G; Banach M
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):353-68. PubMed ID: 24840264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of the high-density lipoprotein (HDL) particle in atherogenesis and potential methods to increase HDL concentrations].
    Birjmohun RS; van der Steeg WA; Stroes ES; Kastelein JJ
    Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2245-50. PubMed ID: 17076358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol.
    Lim S; Park YM; Sakuma I; Koh KK
    Int J Cardiol; 2013 Jun; 166(1):8-14. PubMed ID: 22503572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of low HDL cholesterol.
    Barter PJ
    Aust Fam Physician; 1995 Nov; 24(11):2066-9, 2072, 2074. PubMed ID: 8579543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
    Rosenson RS
    Am Heart J; 2006 Mar; 151(3):556-63. PubMed ID: 16504615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low high-density lipoprotein cholesterol as the possible risk factor for stroke.
    Demarin V; Lisak M; Morović S; Cengić T
    Acta Clin Croat; 2010 Dec; 49(4):429-39. PubMed ID: 21830454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia.
    Oravec S; Dostal E; Dukát A; Gavorník P; Kucera M; Gruber K
    Neuro Endocrinol Lett; 2011; 32(4):502-9. PubMed ID: 21876506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential for CETP inhibition to reduce cardiovascular disease risk.
    Ansell B; Hobbs FD
    Curr Med Res Opin; 2006 Dec; 22(12):2467-78. PubMed ID: 17257461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein(a), cardiovascular disease, and contemporary management.
    Jacobson TA
    Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.